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DRUG EVALUATION
Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma
Florence E Chamberlain a, Chris Wildingb, Robin L Jonesa,b and Paul Huangb
aDivision of Molecular Pathology, The Royal Marsden NHS Foundation Trust, London, UK; bDivision of Molecular Pathology, Institute of Cancer
Research, London, UK
ABSTRACT
Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with
limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine
kinase inhibitor (TKI) with anti-angiogenic and antitumorigenic properties. Whilst targeted agents
including TKIs have been extensively studied in other solid tumors and the sarcoma subtype gastro-
intestinal stromal tumor (GIST), we currently lack effective treatments for the liposarcoma subtype.
Several phase II and III studies of oral TKIs in soft tissue sarcomas have excluded liposarcoma because of
a reported lack of activity following the EORTC 62043 study.
Areas: We review the use of pazopanib in advanced intermediate and high-grade liposarcomas where
complete surgical resection is not possible.
Expert opinion: The current clinical and pharmacological data demonstrate the efficacy of pazopanib
in soft tissue sarcomas, but new data suggest that anti-angiogenic agents may have limited activity in
liposarcoma. Anti-angiogenic TKIs are generally well tolerated and liposarcomas vary in their response
to systemic chemotherapy; hence, there is a role for further exploration of the efficacy of this treatment
amongst the histological subtypes of liposarcoma. This affords further understanding of biomarkers
which may be associated with response to pazopanib and other anti-angiogenic TKI treatments.
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1. Introduction
Liposarcomas (also known as adipocytic soft tissue sarcomas)
are a histological subtype of soft tissue sarcomas. The inci-
dence of liposarcoma in the United States is 0.59 per 100,000
age-adjusted person-years based on data from 1978 to 2001 in
the United States [1], and 0.62 per 100,000 population age-
standardised in the United Kingdom from 2008 to 2010 [2].
However, incidence in the United Kingdom is reported to have
increased by approximately 30% since 1996 and it is therefore
likely that incidence in 2019 is higher [2]. There is male pre-
dominance and 5-year survival is approximately 50–90% (50%
for pleomorphic liposarcomas and 90% for WDLPS) [3].
Liposarcomas arise from adipocyte tissue in any part of the
body; however, these tumors usually originate in the retro-
peritoneum and proximal regions of the limbs. They are clas-
sified into several histopathological subtypes. These subtypes
include well-differentiated (WDLPS)/de-differentiated liposar-
coma (DDLPS), myxoid/round cell and pleomorphic liposar-
coma. WDLPS and DDLPS have distinct histological features
but can be considered part of a spectrum, frequently display-
ing features of both subtypes within the same mass. WDLPS/
DDLPS are the most common subtype of liposarcoma, repre-
senting 50–60% [4]. Myxoid/round cell liposarcoma is seen in
approximately 30–40% of all liposarcomas which are also
considered as part of a spectrum of tumors with distinct
histological features. The remaining 5–10% of liposarcomas is
pleomorphic. As well as histopathological subtype, these
tumors are also classified according to grade (high, intermedi-
ate and low grade) which corresponds to the anticipated
clinical behavior of the tumor [5].
The current standard of care for patients with intermediate and
high-grade liposarcoma includes complete resection for localized
disease where clear margins are possible, with or without radia-
tion. In locally advanced, recurrent or metastatic disease, manage-
ment is tailored to the individual taking into consideration the
tumor size and anatomical location as well as patient factors [6].
Outcomes in surgical re-excision of relapsed disease are poor with
approximately 30% overall survival (OS) at 5 years [7].
Systemic chemotherapy may also be offered to patients with
advanced or metastatic intermediate or high-grade liposarcoma.
Single-agent doxorubicin remains the first line treatment after
neither combination anthracycline and ifosfamide [8] nor high
dose single-agent ifosfamide [9] were able to demonstrate
superiority in OS. However, there was a longer progression-free
survival (PFS) and higher response rate with combination anthra-
cycline and ifosfamide but with a significant increase in grade
3–4 toxicity [9]. Two multicentre randomized phase III trials have
shown both trabectedin [10] and eribulin [11] to have activity in
intermediate and high-grade liposarcoma compared to dacarba-
zine. In the analysis of the liposarcoma subgroup in the eribulin
phase III trial, there was a significant improvement in median OS
among all liposarcoma subtypes (15.6 months vs 8.4 months,
respectively, p = <0.001) as well as PFS (2.9 vs 1.7 months, p =
0.0015) without an increase in toxicity [12].
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CDK inhibitors, which target the CDK amplification seen in
approximately 90% of WDLPS/DDLPS, have also shown pro-
mising results in the phase II trial of palbociclib in liposarcoma
[13]. Studies of other CDK inhibitors in liposarcoma include
ribociclib [14] and abemaciclib [14,15].
2. Body of review
2.1. Overview of the market
2.1.1. Unmet needs of currently available therapies
However, response to systemic chemotherapy varies among the
histological subtypes as well as among grades [16]. Due to the
heterogenicity of DDLPS/WDLPS tumors, response to chemother-
apy may vary according to the tumor components; those with
a predominance of DDLPS component typically respond better
than those with predominant WDLPS component. Response to
chemotherapy is reported between 11% and 24% [4,16,17].
There are limited data supporting the use of chemotherapy in
pleomorphic liposarcoma; and objective response rates are
reported as 33–37% based on retrospective studies [16,18], whilst
myxoid/round cell liposarcomas are typically more responsive to
systemic chemotherapy [16]. There is therefore an unmet need
for effective, well-tolerated treatments in this sarcoma subtype
and the aim of this manuscript is to review the existing evidence
for the use of pazopanib in this rare tumor.
The multicentre phase III placebo-controlled randomized
PALETTE trial demonstrated an increase in median PFS in soft
tissue sarcoma patients treated with pazopanib (4.6 months)
compared to placebo (1.6 months) (p < 0.0001) [19]. However,
the PALETTE trial excluded liposarcomas due to the antecedent
EORTC 62043 phase II study where pazopanib was deemed
inactive in liposarcomas based on pre-defined progression-free
rate (PFR) at 12 weeks of >20% in the first stage of the study
[19,20]. PFR at 12 weeks in the first stage of the liposarcoma arm
of the EORTC 62043 was only 3/17 patients (17.6%), which was
insufficient to enable accrual into the second stage of the study.
However, following a centralized histopathological review, sev-
eral patients were re-assigned to the liposarcoma cohort and PFR
at 12 weeks would have been met in 5/19 patients (26.%) and
liposarcoma would have been included in the second stage of
the study [20]. Had liposarcomas not been deemed inactive
based on the results of the first stage of the EORTC 62043
study [20], liposarcomas may have been included in the subse-
quent PALETTE trial [19]. The SPIRE study performed
a retrospective review of 211 patients treated with pazopanib
via an expanded access scheme. All patients were heavily pre-
treated, however, since the study mirrored the PALETTE trial
inclusion and exclusion criteria, liposarcomas were also excluded
in this study [19,21].
2.1.2. Competitor compounds/classes of compounds are in
the clinic/late development
TKIs have also been under investigation for use in a range of
soft tissue sarcomas in phase II trials including liposarcoma
such as axitinib in the Axi-STS trial [22] sunitinib [23], anlotinib
[24] and regorafenib in the REGOSARC trial [25]. None are
currently licenced for use in liposarcoma.
2.2. Introduction to the compound
Pazopanib (VOTRIENT®) is an oral TKI with anti-angiogenic
effect which is used in the treatment of several solid tumors
including renal cell carcinoma [26]. Pazopanib possesses both
antitumorigenic and anti-angiogenic properties. Its anti-
angiogenic effect is mediated via semi-selective inhibition of
growth factor receptors including VEGFR, PDGFR, FGFR, c-kit.
These proteins are also known as tyrosine kinase receptors
and may be mutated or upregulated in certain tumor cells,
which along with other mechanisms, enables the tumor to
undergo rapid and uncontrolled growth and cell proliferation
[27]. Pazopanib is a synthetic agent from the indazolyl pyrimi-
dines class. It is only slightly soluble at pH values <4 but is
otherwise an insoluble hydrochloride salt and highly plasma
protein bound (>99%) to circulating albumin [28].
In vitro studies of pazopanib have demonstrated an affinity
for inhibition of the tyrosine kinase receptors. These tyrosine
kinase receptors include VEGFR types 1, 2 and 3, PDGFR α and
β, c-Kit and FGFR1 types 3 and 4, and the greatest receptor
affinity is displayed with VEGFR types 1, 2 and 3. In vivo studies
of pazopanib in animal models in a range of tumor xenografts
have demonstrated dose-dependent relationship between
pazopanib and its antitumor activity. In mouse studies, max-
imal inhibition of VEGFR was achieved at a concentration of
Box 1. Drug summary
Drug name (generic) Pazopanib
Phase (for indication under
discussion)
Phase II
Indication (specific to
discussion)
Intermediate and high-grade
liposarcomas
Pharmacology description/
mechanism of action
Pazopanib is a multi tyrosine kinase
inhibitor that inhibits
tumor angiogenesis. This is mediated
via several growth factor receptors
such as VEGFR, PDGFR and FGFR.
Route of administration Oral
Chemical structure C21H23N7O2S
Pivotal trial(s) [19,20,33]
Article highlights
● Pazopanib is an oral multi-target tyrosine kinase inhibitor (TKI) with
anti-angiogenic and anti-tumourigenic properties used in a range of
soft tissue sarcomas.
● Pazopanib was deemed inactive in liposarcomas based on preliminary
results of a phase II study where it did not meet the predefined
criteria for accrual into the second stage of the study.
● Pazopanib was therefore excluded from the subsequent phase III
study of pazopanib in soft tissue sarcomas. However, in the final
analysis of the antecedent phase II study, pazopanib did meet the
predefined criteria in liposarcoma, therefore the opportunity to inves-
tigate its activity in this subtype was missed.
● Pazopanib is well tolerated and demonstrates improved haematolo-
gical toxicity profile compared to existing systemic anticancer
treatments.
● Phase II data supporting the use of pazopanib in intermediate and
high grade liposarcoma are mounting and phase III studies in selected
histological subtypes are warranted.
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approximately 40 µmol/L. In pharmacokinetic studies of 10
participants at 800 mg terminal elimination half-life of pazo-
panib at this dose was 31.1 h, thus there was accumulation at
repeated daily dosing leading to steady state at day 22.
Excretion of pazopanib is found to be predominantly via the
gastrointestinal tract (82.2%) in pharmacokinetic studies and
<5% is thought to be renally excreted [28,29].
In a 2014 animal study, patient-derivedDDLPSorthotopic xeno-
grafts were implanted into nude mice. Mice were either treated
with sterile water, single agent doxorubicin, single agent pazopa-
nib or combination doxorubicin and pazopanib. There was
a reduction in tumor growth in mice treated with either single
agent pazopanib and combination doxorubicin and pazopanib,
however, combination treatment did not improve efficacy above
that of single agent pazopanib [30]. In a 2018 animal study,
a patient-derived orthotopic xenograft was formed by implanta-
tion of doxorubicin-resistant pleomorphic liposarcoma onto the
biceps femoris of nude mice. The xenografts were then either
treated with pazopanib, temozolomide, doxorubicin or no treat-
ment. There was a statistically significant reduction in the size of
the implanted tumor as well as extensive tumor necrosis in the
mice treatedwith pazopanib compared to the untreatedmice (p =
0.0008) [31].
2.3. Clinical efficacy
2.3.1. Phase I studies
The first dose escalation study of pazopanib enrolled 43 patients
with a range of solid tumors (including renal cell carcinoma, mel-
anoma, lung, and soft tissue sarcomas). The patients were treated
withpazopanibdoses increasing from50mg three timesweekly to
2000 mg daily in cohorts. The primary endpoint was safety whilst
secondary endpoints included biomarkers and clinical efficacy.
Frequently reported toxicities of grade 3–4 were nausea (n = 1),
fatigue (n = 1), hypertension (n = 6) and vomiting (n = 1).
Hypertension was dose dependent but responded to treatment
discontinuation and standard anti-hypertensive treatment in all
cases [32]. The study subsequently recruited to a dose expansion
phase of pazopanib at doses of 300 mg twice daily and 800 mg
once daily in a further 20 patients, all with solid tumors. Toxicities
were reported in similar frequencies as in the dose escalation
study – themajority of whichwas grade 1–2. Dose-limiting toxicity
was seen in four participants in daily dosing of 50mg, 800mg, and
2000 mg. The drug reached steady state in doses ≥800 mg daily
and clinical benefit was seen in doses ≥800 mg once daily or
300 mg twice daily. Three patients had partial response, and 14
patients had stable disease lasting >6 months. Among the cohort
of patientswith soft tissue sarcomas, 3/8 (37.5%)maintained stable
disease for >6 months (chondrosarcoma (n = 1), leiomyosarcoma
(n = 1) and GIST (n = 1)). Although maximum tolerated dose was
not reached within this study, steady-state exposure of pazopanib
plateaued at doses >800mg; therefore, this was the dose selected
for ongoing clinical studies [32].
2.3.2. Phase II studies
The phase II EORTC 62043 study assessed pazopanib in several soft
tissue sarcoma subtypes including liposarcoma. In this study, pazo-
panib was deemed inactive in liposarcomas, based on the prede-
fined study requirement that pazopanib should achieve a PFRat 12
weeks of >20% in any subtype of sarcoma for that subtype to
continue to full accrual in the trial [20]. The phase III PALETTE trial
excluded liposarcomas on this basis [19]. However, in the final
analysis of the EORTC 62043 study, two patients were reclassified
into the liposarcoma cohort from another cohort after central
pathological review, therefore, 5/19 liposarcoma patients (26.3%)
met the primary endpoint at the end of the trial [20].
Despite the preliminary findings of pazopanib inactivity for
liposarcoma in the EORTC 62043 study, a phase II multicentre
study evaluated the use of pazopanib in 41 patients with
advanced and metastatic intermediate-grade or high-grade lipo-
sarcoma. Participants were treated with once-daily pazopanib at
a dose of 800 mg in 28-day cycles until disease progression
which was evaluated every three cycles. The primary endpoint
was PFR at 12 weeks, and secondary endpoints were safety and
tolerability. Overall median PFR at 12 weeks was 4.4 months with
OS of 12.6 months. The 41-patient cohort was comprised of 27
patients with DDLPS, 12 patients with myxoid liposarcoma, 2
patients with pleomorphic liposarcoma, whilst WDLPS was
excluded from study recruitment. PFR at 12 weeks for DDLPS
was 20/27 patients (74.1%) and for myxoid LPS 8/12 patients
(66.7%). Subgroup analysis of the pleomorphic liposarcoma
group was not considered due to the small group size [33].
A further phase II trial also explored the use of pazopanib in
patients with advanced intermediate or high-grade liposarcoma
and results were presented ahead of publication in 2016. Fifty-two
patients were recruited, divided into two cohorts (WDLPS/DDLPS
and myxoid/round cell) with pleomorphic LPS excluded. Primary
endpoint was PFS at 12 weeks. The myxoid/round cell cohort was
closed to recruitment early after 15 patients due to failure to meet
the primary endpoint, whilst in the WDLPS/DDLPS subgroup,
43.2% of patients met the primary endpoint. In the WDLPS/
DDLPS subgroup, median PFS and OS was 3.5 and 16.4 months,
respectively; whilst in themyxoid/round cell cohort it was 1.99 and
22.3 months, respectively. However, no objective response as per
RECIST 1.1 was demonstrated on local review and final results are
awaited [34].
The provisional results of the phase II randomized EPAZ trial
were recently presented ahead of publication. The study com-
pared the efficacy of pazopanib to single-agent doxorubicin in
elderly patients with locally advanced and metastatic soft tissue
sarcomas, including liposarcomas. The primary endpoint of the
study was non-inferiority of pazopanib to doxorubicin and sec-
ondary endpoints included OS, toxicity, and quality of life assess-
ments. One hundred and twenty patients were randomized in
a 2:1 ratio to pazopanib and doxorubicin, respectively. For both
PFS and OS, pazopanib showed non-inferiority compared to
doxorubicin in this cohort with similar quality of life measure
outcome, however, with the benefit of an absence of hematolo-
gical toxicity in the pazopanib cohort [35].
2.3.3. Phase III studies
There are currently no published phase III studies which inves-
tigate the use of pazopanib in the treatment of liposarcomas.
2.3.4. Post-marketing studies
A multicentre retrospective review of post-marketing sur-
veillance data of patients treated with pazopanib for soft
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tissue sarcoma identified 156 patients across 37 Japanese
institutions. Pazopanib has been licenced for use in pre-
treated liposarcoma in Japan despite exclusion from the
PALETTE trial. The primary endpoint of this study was to
evaluate the efficacy of pazopanib in soft tissue sarcomas
outside the setting of a clinical trial. Secondary endpoints
included safety, PFS and radiological response to pazopanib.
Mean follow up after the commencement of pazopanib was
11.4 months. Of the 32 included patients with liposarcoma,
17 had DDLPS, 11 myxoid liposarcoma and 4 had pleo-
morphic liposarcoma. Average dose was 609 mg, with
grade 3–4 events reported in 48/156 (30.8%) of participants,
of which hypertension was the most frequently seen (10/
156 participants). Pneumothorax (8/156 participants), liver
dysfunction (8/156 participants), thrombocytopaenia (8/156
participants) grade 3–4 were also frequently observed.
Adverse events of any grade occurred in 127/156 partici-
pants (81.4%) resulting in nearly half of the study cohort
(70/156) requiring a dose reduction whilst on treatment.
Thirty-one patients were not eligible for evaluation of
tumor response (as per RECIST criteria) due to early discon-
tinuation of pazopanib (n = 14), clinical progression (n = 9)
and hospital admission (n = 8). 87/125 patients (69.6%) had
a partial response or stable disease. However, only 3/22
(14%) of patients with liposarcoma achieved at least stable
disease with a median PFS of 8 weeks compared to 17.7
weeks in all sarcoma tumor types [36].
2.3.5. Other studies of interest
In the multicentre phase, II REGOSARC trial 182 patients with
anthracycline pre-treated soft tissue sarcomas were randomized
in a 1:1 ratio to receive the oral TKI regorafenib or a placebo. The
primary endpoint was PFS according to RECIST. Although there
was a statistically significant improvement in PFS in the synovial
sarcoma cohort compared to placebo, this was not seen in
liposarcomas, where PFS was 1.1 months with regorafenib and
1.7 months with placebo (p = 0.07). Results for a further arm
which compares the above cohorts of patients who have
received prior treatment with pazopanib are awaited [25].
Two other anti-angiogenic TKIs have also recently demon-
strated efficacy in a range of soft tissue sarcomas including
liposarcomas. A phase II single center study in the United States
treated 48 patients with advanced soft tissue sarcomas with
sunitinib. PFS in the liposarcoma cohort was 3.9 months with
OS 10.1monthswarranting further investigation in a phase III trial
[23]. Results of the safety and efficacy phase II trial of anlotinib in
soft tissue sarcomas were recently published. The primary end-
point was PFS at 12 weeks, with anlotinib deemed an
active second-line agent in soft tissue sarcomas if PFS12 weeks
was greater than 40%. In the study, PFS at 12weekswas observed
in 68% of all sarcoma subgroups (n = 166) and in 63% of patients
with liposarcoma (n = 13), whilst overall median PFS across all
sarcoma subgroups was 5.6 months with a median PFS in the
liposarcoma subgroup of also 5.6 months. Median OS was 12
months across all subgroups and 13 months in the liposarcoma
cohort [24].
2.4. Safety and tolerability
The toxicity profile of pazopanib is comparable to other oral
TKIs. The most frequently reported toxicity is hypertension
which is dose dependent and may be present in up to 80%
of patients treated with pazopanib. It is mediated via
a reduction in nitric oxide and an increase in endothelin
production within the vascular endothelium leading to vaso-
constriction [37]. Other toxicities commonly reported in pazo-
panib use include reductions of ≥15% in left ventricular
ejection fraction (10% of patients), dysrhythmias (<5% of
patients) hair depigmentation (40% of patients) and hypothyr-
oidism (<10% of patients) [26,38,39].
Hepatotoxicity from pazopanib is frequently reported, and
it is thought that grade 1–2 hepatotoxicity occurs in 30–50%
of patients, whereas grade 3–4 hepatitis occurs in <10% of
patients. A meta-analysis of fatal hepatotoxicity in patients
treated with pazopanib treated in 10 clinical trials found an
incidence of <1% and relative risk 2.51 (p = 0.55). Onset of
hepatotoxicity is typically within 4 months of commencing
pazopanib and requires careful monitoring, dose reduction
and treatment discontinuation in certain cases [40].
2.5. Regulatory affairs
Currently, there are no randomized data to support the reg-
ulatory approval of pazopanib for any liposarcoma subtype.
Pazopanib and other anti-angiogenic agents are currently only
used within the context of clinical trials for the treatment of
liposarcomas.
2.6. Conclusion
Although currently used for a range of pre-treated soft tissue
sarcomas, the role of pazopanib in intermediate and high-
grade liposarcomas remains unclear and requires further
investigation in phase III studies. A summary of published
trial data specific to the use of pazopanib in liposarcoma can
be found in Table 1. Provisional data from the EORTC 62043
study [20] demonstrated a lack of efficacy in pazopanib to
treat liposarcomas which led to exclusion of the liposarcoma
subtype from the phase III PALETTE study [19]. However,
following reclassification of two patients in the EORTC 62043
study, the liposarcoma cohort would have met the predefined
study requirement that pazopanib should achieve a PFR at 12
weeks of >20%, warranting further phase III study [20].
Activity of pazopanib against liposarcoma is supported by
animal studies in DDLPS [30] and pleomorphic [31] orthotopic
xenografts. A phase II multicentre study of pazopanib in
patients with advanced and metastatic intermediate-grade or
high-grade liposarcomas was also supportive of pazopanib
efficacy in the DDLPS and myxoid LPS subtypes [33].
However, another phase II trial of pazopanib in liposarcomas
closed their myxoid/round cell cohort to recruitment early due
to failure to meet the primary endpoint, whilst in their WDLPS/
DDLPS subgroup, 43.2% of patients met the primary endpoint
508 F. E. CHAMBERLAIN ET AL.
[34]. The provisional results of the phase II randomized EPAZ
trial are also supportive of the activity of pazopanib in lipo-
sarcoma by demonstrating non-inferiority to doxorubicin in
elderly patients [35].
However, this activity was not demonstrated in the
Japanese post-marketing study where only 14% of patients
achieved at least stable disease with a median PFS of 8 weeks,
half that of the other sarcoma subtypes [36].
Due to the heterogenicity of liposarcoma histopathological
subtypes a variable response to systemic anticancer treat-
ments is expected and it may be possible to explore this
further with a biomarker led prospective study.. Given the
vast heterogeneity between liposarcoma subtypes and
grade, any future studies should ensure they stratify patients
according to subtype to determine if there are differences in
the response to pazopanib or other targeted agents. However,
we are yet to identify a biomarker which can help accurately
predict response to pazopanib and other oral TKI agents. This
should be a focus on further work so that we can select the
correct cohort of patients who will derive benefit from
pazopanib.
The toxicity profile and frequency of adverse events with
pazopanib have been consistent in all studies of pazopanib in
liposarcomas [20,33–36]. However, in these studies, dose
reductions are occurring in approximately 50% of patients;
therefore, patients are not receiving the 800-mg dose which
was established as effective in early studies [32]. However, in
the non-trial population, patients are often commenced on
a lower starting dose (200–600 mg) or significantly dose
reduced at clinician discretion to ensure treatment tolerability.
Caution must be taken with the management of toxicities
(particularly cardio-toxicity [38] and hepatotoxicity [40]) with
appropriate surveillance, prompt treatment, specialist referral
and treatment adjustment where required.
In the phase II EPAZ trial of elderly patients, whilst there
was no statistical difference in the quality of life measures,
there was a significant improvement in hematological toxicity
but with a similar burden of non- hematological toxicity com-
pared to doxorubicin [35]. Although further investigation is
required, pazopanib is potentially a good alternative option
for elderly patients that are unfit for or unable to tolerate
other systemic therapies.
Additional advantages of pazopanib compared to available
treatments for advanced or metastatic liposarcoma includes
oral administration whereas most existing systemic therapies
for liposarcoma are delivered intravenously. Oral treatment
offers the patient more convenience and flexibility of admin-
istration and is less invasive compared to intravenous prepara-
tions. Additionally, oral preparations reduce the burden of
resources required to deliver the treatment compared to intra-
venous preparations.
The data to support the use of other TKIs in the treatment
of intermediate and high-grade liposarcomas also remains
unclear. Although regorafenib in the REGOSARC trial did not
meet the primary endpoint of improved PFS vs placebo in the
liposarcoma cohort [25], both anlotinib [24] and sunitinib [23]
performed well against placebo in the liposarcoma arms of
their respective phase II trials. Finally, the role of combination
pazopanib and other systemic therapies is currently beingTa
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explored further with both topotecan [41] and gemcita-
bine [42].
3. Expert opinion
The use of pazopanib in treating intermediate and high-grade
liposarcoma shows promise [33–35] despite exclusion from
the phase III PALETTE study [19] for inactivity in phase II trials
[20]. Its main advantage includes its oral route of administra-
tion [29] compared to licensed existing systemic treatments
which are delivered intravenously and similar quality of life
measures to the current first-line treatment with doxorubicin
[35]. Improvement in hematological toxicity profile but with
a similar burden of non-hematological toxicity compared to
doxorubicin makes pazopanib a good alternative for patients
unfit for systemic chemotherapy [35].
Whilst pazopanib is unlikely to displace doxorubicin as first-
line treatment for intermediate and high-grade liposarcoma
[8], it is possible that pazopanib could be used as an alter-
native to trabectedin [10] or eribulin [11] due to its favorable
hematological side effect profile [35].
The risks and benefits of pazopanib have been established
in other tumor types [39] therefore oncologists are unlikely to
be reluctant to prescribe pazopanib, and many will have
experience of using it in other soft tissue sarcomas [19].
However, the evidence for the efficacy of pazopanib in
advanced intermediate and high-grade liposarcomas is con-
fined to phase II studies and a post-marketing study. Further
evaluation of the DDLPS and myxoid LPS subtypes with
a prospective randomized phase III study is required before
oncologists will start prescribing pazopanib to patients with
liposarcoma. It is possible that in five years time pazopanib
will be being studied in a randomized prospective phase III
study based on the increasing body of early phase studies
supporting its activity.
Finally, there also remains an ongoing unmet need for
effective treatments for this subtype of sarcoma and for
further options for patients who have exhausted conventional
lines of therapy.
In addition to pazopanib, the CDK inhibitor palbociclib has
shown promising results in the phase II trial [13] and other
CDK inhibitors are currently under early phase investigation
for liposarcoma including ribociclib [14] and abemaciclib [15].
It is likely that CDK inhibitors will have a role to play in the
management of DDLPS in the future. The oral TKI sunitinib
[23] and anlotinib [24] have both also demonstrated efficacy in
the phase II trial warranting further investigation in a phase III
trial. It is possible that these drugs could be approved for the
treatment of intermediate-grade and high-grade liposarcomas.
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